KOVACH JOHN S has a total of 19 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2008. It filed its patents most often in United States. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and medical technology are CUREGENIX INC, KEMPHARM INC and INDEPENDENT PHARMACEUTICA AB.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 19 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Medical technology | |
#4 | Measurement | |
#5 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Heterocyclic compounds | |
#4 | Electrotherapy | |
#5 | Microorganisms | |
#6 | Analysing materials | |
#7 | Special acyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Kovach John S | 19 |
#2 | Johnson Francis | 7 |
#3 | Zhuang Zhengping | 4 |
#4 | Samudrala Ramakrishna | 3 |
#5 | Lu Jie | 2 |
#6 | Hall Matthew | 1 |
#7 | Yang Chunzhang | 1 |
#8 | Chang Ki-Eun | 1 |
#9 | Gupta Ramesh C | 1 |
#10 | Lonser Russell | 1 |
Publication | Filing date | Title |
---|---|---|
US2017136008A1 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer | |
US2016264593A1 | Protein phosphatase inhibitors that cross the blood brain barrier | |
US2016009727A1 | Sanguinarine analog pp2c inhibitors for cancer treatment | |
US2016008336A1 | Hdac inhibitors for the treatment of traumatic brain injury | |
US2012135522A1 | Methods of modulating cell regulation by inhibiting p53 | |
US2010029484A1 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |